The eye's lens is where entropy finally wins. It’s a closed system where proteins have no exit; they just pile up damage until they lose solubility and phase-separate into the refractive mess we call cataracts. It’s usually a slow, predictable decline. But modern oncology has found a way to force this same proteomic insolvency onto high-turnover tissues in just a few months.

We celebrate five-year survival rates while ignoring the reality that we’ve essentially turned a thirty-year-old survivor’s proteome into a seventy-year-old’s graveyard. Chemotherapy and radiation aren't just hitting malignant cells; they’re imposing a systemic proteostasis debt the body can’t ever fully repay. By the time the cancer is declared "gone," we’ve often triggered a widespread collapse of the protein-folding machinery that mimics the final stages of lens aging.

Nobody's quite sure what happens when a survivor’s cardiac or neuronal proteome undergoes forced Liquid-Liquid Phase Separation (LLPS) from the massive genotoxic stress of treatment. We track telomeres and inflammatory markers, but we aren't looking at the patient’s solubility profile. We're likely creating a generation of biological ghosts—people whose tumors are dead, but whose healthy cells are cluttered with the same irreversible, insoluble aggregates that drive age-related decline.

Winning a fight against cancer isn't much of a victory if it forces the rest of the body into premature molecular crowding. We're treating the "seed" by salting the "earth" of the systemic proteostasis network. We need a real bridge between oncology and protein-folding biophysics. We have to develop chaperone-mimetic shields—biological "alpha-crystallins" for the whole body—that can be co-administered to stop the iatrogenic aggregation that currently defines "survival." If we don't address the proteomic debris field we leave behind, we aren't extending life; we’re just changing the cause of death to a more lingering, aggregated version of itself.